MK-2870-012

About this trial

Patient Profile

participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery

Where’s this trial being run?

Bon Secours Cork, St Vincents University Hospital, and University Hospital Galway

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: MK-2870-012
Number: 24-58
Full Title:

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery

Principal Investigator: Dr Janice Walsh
Type: Industry Sponsored
Sponsor:

Merck Sharp & Dohme LLC

Recruitment Started: Global: June 2024
Ireland: November 2024
Global Recruitment Target: 1530
Ireland Recruitment Target: 7